Dichloropane
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Dichloropane (RTI-111) is a synthetic stimulant of the phenyltropane class. It is a structural analog of cocaine, substantially more potent at the transporters cocaine targets. It blocks the recycling of dopamine, serotonin, and norepinephrine from the synapse, prolonging their activity and producing stimulation with an unusual serotonergic character.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, dopamine reuptake inhibitors, stimulants +1 morecocaine, dopamine reuptake inhibitors, stimulants, phenyltropanes show less
Synthesized in 1993, dichloropane was immediately described as one of the most potent cocaine analogs ever made.[2] It was studied as a potential cocaine addiction treatment under the designation RTI-111 but was never advanced to human trials.[3] It surfaced on the research chemical market around 2010 and drew a European drug monitoring alert in 2016.[4]
Subjective effects include euphoria, stimulation, focus enhancement, mood elevation, and a reported affective warmth not typical of most stimulants. The experience is a sustained, moderate-onset stimulation — somewhere between cocaine and entactogenic stimulants, shaped by the compound's unusually strong serotonin component. Anxiety, racing heart, and post-use low mood are characteristic downsides.
Dichloropane is moderately addictive; no lethal dose or human toxicity data exist.safety citation needed Cardiovascular strain lasts longer than cocaine, and combining it with serotonin-raising drugs can trigger a life-threatening overheating and seizure response. No controlled human studies exist — everything known comes from animal research, structural analogy to cocaine, and three forensic cases.
History[edit]
Discovery
Dichloropane was first synthesized in 1993 by Peter Meltzer and colleagues.[2] It emerged from a program evaluating phenyltropane analogs as cocaine binding inhibitors and was described as "one of the most potent cocaine congeners yet reported".[2] It received the designation RTI-111 within Research Triangle Institute's phenyltropane program.[3]
Preclinical development
The RTI program sought a long-acting, low-abuse-potential treatment for cocaine addiction — conceptually analogous to methadone for opioid dependence. Dichloropane was tested in primate and rat self-administration studies[5][6] and as a PET imaging probe for dopamine pathways,[7] but was not selected for clinical advancement; RTI-336 went forward as the program's lead.[3]
Research chemical market
Dichloropane appeared on the online research chemical market around 2010.[4] Forensic seizures in Sweden and Slovenia prompted a formal European early warning notification in 2016.[4] Three human forensic cases were documented, with blood concentrations around 1.0 ng/mL.[8]
Chemistry[edit]
Structural class
Dichloropane belongs to the phenyltropane family — synthetic analogs of cocaine built on the same tropane ring skeleton. Its defining feature is 3,4-dichloro substitution on the phenyl ring, which increases lipophilicity and strengthens transporter binding.[13]
Its molecular formula is C₁₅H₁₇Cl₂NO₂ (MW 314.2 g/mol), and it belongs to the RTI compound series alongside troparil, RTI-112, and RTI-336.[1][3]
Molecular identity
Two distinct molecules are sold as "dichloropane" or "RTI-111": the nortropane form (CAS 146725-34-0, MW 314.2), confirmed by PubChem and NCATS;[1] and the N-methyl tropane form (CAS 150653-91-1, MW 364.7), sold by some chemical vendors.[14] PsychonautWiki lists an IUPAC name corresponding to the N-methyl form,[4] contradicting the PubChem/NCATS assignment. This article follows the nortropane assignment, consistent with enhanced transporter affinity from N-demethylation.[15]All physical property values are computationally predicted; no experimentally measured data have been published.[16]
Pharmacology[edit]
Mechanism of action
Dichloropane blocks all three major monoamine transporters simultaneously, preventing dopamine, serotonin, and norepinephrine from being cleared from the synapse.[1] The result is stronger and longer-lasting signaling across all three systems. Dopamine drives reward and euphoria; serotonin modulates mood and emotional warmth; norepinephrine drives arousal and heart rate.[2]
The nortropane structure gives dichloropane unusually strong serotonin and norepinephrine activity compared to most phenyltropanes, producing a more balanced monoamine profile than dopamine-selective cocaine analogs.[15] Unlike Cocaine, it does not block sodium channels and lacks local anesthetic activity.[4]
Pharmacokinetics
No human pharmacokinetic data exist. Animal studies show slower brain uptake and longer duration than cocaine,[4] and PET imaging in primates confirmed binding in both dopamine-rich and serotonin-rich brain regions.[7] The primary breakdown product is presumed to be an ester hydrolysis metabolite,inferred detected in human forensic specimens at approximately 1.0 ng/mL.[8]
Neuroscience[edit]
Where it acts
Dopamine reuptake inhibitor in the brain's mesolimbic pathway — from the ventral tegmental area to the nucleus accumbens — drives reinforcement and euphoria. Dichloropane functions as a positive reinforcer in primate self-administration studies[5] and produces cocaine-like effects in rat discrimination tests,[6] confirming engagement of this reward circuit.
The strong SERT component sets dichloropane apart from most stimulants. PET imaging confirmed accumulation in serotonin-rich brain regions,[7][17] suggesting serotonergic modulation that may introduce affective warmth absent from purely dopaminergic stimulants.
Why it matters
How fast dopamine rises in the brain's reward center shapes how reinforcing a stimulant feels. Rapid surges produce stronger compulsive pull; slower, sustained increases produce weaker reward responses.[18][19] Dichloropane's slower onset compared to cocaine may generate less compulsive pursuit — though this has not been confirmed in humans.
Key unresolved questions include whether dichloropane's balanced transporter inhibition produces qualitatively different subjective effects than dopamine-selective stimulants, whether its serotonergic component confers entactogen-adjacent properties, and whether the slower onset translates to reduced abuse liability in humans as predicted by primate models. The pharmacokinetic basis for the reported 2–4 hour insufflated duration also remains unknown.
Subjective Effects[edit]
The experience is a sustained stimulant state — not the rapid compressed rush of cocaine but a more gradual buildup that plateaus and holds. The unusually strong serotonin component gives it affective warmth that most stimulants lack, lending the experience an emotional quality somewhere between a stimulant and an entactogen.
The closest familiar comparator is cocaine, but dichloropane is slower, longer, and warmer in character. It is more balanced across serotonin and dopamine than most commonly encountered stimulants, which makes it pharmacologically unusual — though not well-known enough to have a clear cultural reference point.
Effect Grid
Pronounced stimulation and clear cognitive euphoria define the experience. Focus enhancement and thought acceleration are significant — sustained attention and motivation enhancement are readily apparent. The serotonergic component may produce an affective warmth or subtle entactogen-adjacent quality alongside conventional stimulant effects. Disinhibition and sociability enhancement are noticeable.
Cardiovascular effects become notable: elevated heart rate, vasoconstriction, and possible abnormal heartbeat. Appetite suppression is clear. Bruxism and excessive sweating may emerge. Wakefulness is sustained throughout the experience, with a dehydration sensation prompting fluid intake.
Insufflated duration spans 2–4 hours total, while smoked effects compress into 40–75 minutes. Compulsive redosing urge may emerge, particularly via the smoked route. Sleep will be disrupted for several hours post-dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Touch enhancement · Tinnitus
Pupil dilation · Body high · Dry mouth · Heart rate perception changes · Insomnia · Muscle tension · Physical fatigue · Restlessness · Respiratory stimulation · Excessive sweating · Dehydration sensation · Breathing alteration · Bruxism · Bodily lightness · Headache · Tactile euphoria · Sexual arousal enhancement · Abnormal heartbeat · Pain suppression · Sexual arousal suppression · Dizziness · Nasal congestion · Nausea · Tingling / electric sensations · Trembling · Brain zaps
Heart rate perception changes · Insomnia · Muscle tension · Physical fatigue · Restlessness · Respiratory stimulation · Excessive sweating · Dehydration sensation · Breathing alteration · Bruxism · Bodily lightness · Headache · Tactile euphoria · Sexual arousal enhancement · Pain suppression · Sexual arousal suppression · Dizziness · Nasal congestion · Nausea · Tingling / electric sensations · Trembling · Brain zaps
Motivation enhancement · Focus enhancement · Motivation suppression · Information processing enhancement · Analysis enhancement · Language enhancement · Thought organization · Cognitive dysphoria · Pattern recognition enhancement · Thought loops · Creativity enhancement · Memory enhancement · Thought deceleration · Aesthetic enhancement · Thought disorganization
Analysis enhancement · Language enhancement · Thought organization · Cognitive dysphoria · Pattern recognition enhancement · Thought loops · Creativity enhancement · Memory enhancement · Thought deceleration · Aesthetic enhancement · Thought disorganization
Anhedonia · Dysphoria · Mania
Communication enhancement · Sociability enhancement · Social connection · Flow state
Timeline
Gradual emergence of stimulation over 15-30 minutes as dichloropane absorbs through nasal mucosa. Subtle alertness increase and mild heart rate elevation are the first perceptible signs.
Progressive intensification of stimulant effects. Focus enhancement, thought acceleration, and appetite suppression become clearly apparent. Cardiovascular activation builds steadily.
Full stimulation with cognitive euphoria, sustained focus, and motivation enhancement. Cardiovascular effects are prominent. The serotonergic component may contribute subtle mood warmth beyond conventional stimulant affect.
Gradual decline over 60-90 minutes. Residual wakefulness and appetite suppression persist. Irritability, dysphoria, and mild depression may emerge as monoamine levels normalize.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 9 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · dopamine reuptake inhibitors · stimulants
Toxicity
No controlled toxicity data, lethal dose values, or organ-specific toxicity studies have been published for dichloropane.safety citation needed All risk assessments are inferred from class pharmacology.
Cardiovascular toxicity
Dichloropane raises heart rate and blood pressure, and constricts blood vessels — driven by increased dopamine and norepinephrine activity.[1] Because its duration exceeds cocaine's, this cardiovascular strain persists longer per dose.
Unlike cocaine, it does not block sodium channels,[4] which may reduce the risk of certain heart rhythm disturbances. Blood vessel spasm, reduced blood flow to the heart, and stress-related cardiac damage remain class-level risks.
Overheating risk
Blocking both dopamine and serotonin reuptake simultaneously increases the risk of dangerous overheating, particularly in hot environments or during physical exertion.inferred This is a documented class effect of dual DAT/SERT inhibitors.
Seizure risk
Potent stimulants lower the seizure threshold in a dose-dependent way. No seizure data specific to dichloropane have been published.safety citation needed
Forensic case data
Three human forensic cases positive for dichloropane were documented, with blood concentrations around 1.0 ng/mL and urine concentrations around 4.5 ng/mL.[8] No fatalities directly attributable to dichloropane were identified in the available literature.
Psychological risks
No controlled human studies have assessed dichloropane's psychological risks. As a stimulant-class SNDRI, the following are anticipated:
- Stimulant psychosis: High-dose or prolonged use can trigger paranoia, agitation, and hallucinations from excessive dopamine activity.inferred
- Anxiety and panic: Higher doses can produce acute anxiety and panic driven by norepinephrine-driven arousal.
- Post-use crash: After sustained use, monoamine depletion brings rebound effect low mood, anhedonia, and depressive symptoms — especially after binge use.
- Compulsive redosing: Dichloropane functions as a positive reinforcer in primate models,[5] indicating real abuse liability, though slower onset may partially reduce this risk compared to cocaine.[20]
Tolerance and dependence
No substance-specific tolerance or dependence data exist.safety citation needed Tolerance develops through dopamine downregulation, and the phenyltropane series showed an absence of behavioral sensitization in some animal models,[3] suggesting a different tolerance trajectory than cocaine. The strong serotonin component may also cause serotonin system desensitization when use stops — with mood disturbances similar to antidepressant discontinuation.
The phenyltropane class generally shows lower reinforcing strength than cocaine due to slower transporter occupancy onset,[18][21][19] but dichloropane functions as a positive reinforcer in primate models and produces cocaine-like effects in discrimination studies,[5][6] confirming real abuse potential.[20]
Drug interactions
No published interaction studies exist; all assessments are inferred from the SNDRI mechanism.safety citation needed Combining with MAOIs (phenelzine, tranylcypromine, or high-dose selegiline) risks serotonin syndrome — a dangerous overheating and seizure response from serotonin accumulation that can be fatal. SSRIs and SNRIs add further reuptake inhibitor and raise the same risk.
Combining with other stimulants — amphetamines, methylphenidate, cathinones, or cocaine — compounds cardiovascular stress through additive dopamine and norepinephrine effects. Alcohol and depressants can mask stimulant impairment while cardiovascular strain continues. Blood pressure medications may become less effective against stimulant-driven cardiovascular activation.
Contraindications
No substance-specific contraindication data exist.safety citation needed
Absolute (class-inferred):
- Concurrent MAOI use: Risk of serotonin syndrome — potentially fatal
- Serious heart conditions: Including uncontrolled high blood pressure, recent heart attack, heart failure, or significant rhythm disturbances
- Pheochromocytoma: catecholamine-potentiating compounds risk dangerous blood pressure spikes
Relative (class-inferred):
- Seizure disorders: Stimulants lower the seizure threshold
- Anxiety disorders and psychotic conditions: Norepinephrine and dopamine potentiation may worsen symptoms
- Overactive thyroid: Additive stimulant effects with existing catecholamine excess
- Concurrent serotonergic medication: SSRIs, SNRIs, triptans, tramadol — elevated serotonin syndrome risk
- Pregnancy and lactation: No reproductive safety data exist; stimulant-class compounds are generally contraindicatedinferred
Harm Reduction[edit]
Forms & Identification
Dichloropane typically circulates as a white powder, visually indistinguishable from many other stimulant research chemicals. Material sold as "RTI-111" or "dichloropane" may contain either the nortropane or N-methyl tropane form — or neither. Reagent testing can confirm a tropane-class compound is present but cannot distinguish between structural variants or verify purity.
Given the absence of established dose–response data in humans, treating any batch as potentially more potent than expected is prudent.
Guidelines
- Test every batch with reagent kits before use
- Start with the lowest plausible dose and wait the full onset period before considering redosing — insufflation onset can take 15–30 minutes
- Keep water accessible and drink regularly to offset dehydration and overheating risk
- Avoid hot, crowded environments where overheating risk is highest
- Do not use alone — have a sober companion present, especially with an unfamiliar batch
- Set a hard stop time; stimulant sessions that extend through the night carry compounding cardiovascular and psychological risk
- Eat a meal beforehand — stimulants suppress appetite, and low blood sugar worsens physical stress
Set & Setting
A calm, familiar environment with trusted company reduces the likelihood of anxiety escalation. Stimulant experiences amplify existing mental states — entering a session anxious, agitated, or sleep-deprived increases the risk of panic and compulsive redosing. Plan session duration in advance and set a firm limit on redosing before the first dose.
Aftercare & integration. The post-stimulant crash may include low mood, fatigue, irritability, and difficulty concentrating as monoamine systems recover. Prioritize sleep — use blackout curtains and avoid screens if the session extended into nighttime hours.
Eat nutrient-dense meals, particularly foods rich in protein and complex carbohydrates, to support neurotransmitter precursor replenishment. Do not redose to fix the comedown — this extends recovery time and increases dependence risk. If low mood persists beyond 48–72 hours, or if cravings feel difficult to manage, speak with a healthcare provider.
Recovery & Support
Compulsive stimulant use can develop gradually, particularly when use shifts from planned sessions to spontaneous redosing or daily patterns. Warning signs include increasing dose frequency, neglecting responsibilities during or after use, and difficulty maintaining planned abstinence periods.
Support resources include SAMHSA's National Helpline (1-800-662-4357), free, confidential, and available 24/7. Cognitive behavioral therapy has the strongest evidence base for stimulant use disorders. Peer support through groups such as SMART Recovery offers non-12-step alternatives for those who prefer structured self-management approaches.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing are immediate red flags. Severe agitation, paranoid delusions, or self-harm behavior also require emergency intervention.
Immediate steps:
- 1. Call emergency services immediately if any red flag is present
- 2. Move the person to a cool, quiet space
- 3. Remove excess clothing to aid cooling
- 4. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 5. Do not restrain unless there is immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (dichloropane / RTI-111), the amount taken if known, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for stimulant overdose. Medical treatment is supportive — cooling, sedation, and cardiovascular monitoring.
Legal Status[edit]
As of May 2026, dichloropane is not specifically scheduled under most national drug control frameworks but falls within structural analog and psychoactive substance legislation in several jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not explicitly scheduled | Subject to the Federal Analogue Act (21 U.S.C. § 813) as a structural analog of cocaine (Schedule II); prosecution requires evidence of intent for human consumption |
| United States (Vermont) | Explicitly regulated | Listed in Vermont Code of Regulations 13-140-011-X as "Dichloropane; RTI-111; 0-401";[9] misclassified under "Hallucinogenic Drugs" category |
| United Kingdom | Covered under Psychoactive Substances Act 2016 | Blanket ban on psychoactive substances not otherwise exempted; no specific scheduling under the Misuse of Drugs Act 1971 |
| European Union | EMCDDA early warning issued (2016) | Formal notification EU-EWS-RCS-FN-2016 0065 following forensic seizures in Sweden and Slovenia;[4] no EU-wide scheduling confirmed; member state legislation varies |
| Sweden | Likely controlled | Site of first forensic seizure (late 2016); national NPS legislation likely applies |
| Slovenia | Likely controlled | Second 2016 seizure sample; national NPS legislation likely applies |
| Canada | Not explicitly named | Not listed in the Controlled Drugs and Substances Act; may fall under analogue provisions |
| Australia | Unclear | Not found in the national Poisons Standard; state and commonwealth psychoactive substance amendments may apply |
Analog and classification considerations
The Federal Analogue Act treats any substance substantially similar in structure or pharmacological effect to a Schedule I or II controlled substance as controlled when intended for human consumption. As a direct structural analog of cocaine, dichloropane falls within this scope.
Vermont lists dichloropane under "Hallucinogenic Drugs" — a pharmacological misclassification.[9] Dichloropane has no hallucinogenic mechanism; the placement reflects administrative convenience rather than pharmacological assessment.
references
- [1]
- [2] ^abcdMeltzer PC, Liang AY, Brownell AL, Elmaleh DR, Madras BK (1993) Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging — Journal of Medicinal Chemistry PMID:8464040
- [3]
- [4]
- [5] ^abcdRanaldi R, Anderson KG, Carroll FI, Woolverton WL (2000) Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine — Psychopharmacology PMID:11255920
- [6] ^abcCook CD, Carroll IF, Beardsley PM (2001) Cocaine-like discriminative stimulus effects of novel cocaine and 3-phenyltropane analogs in the rat — Psychopharmacology PMID:11797070